Splenectomised Patients Clinical Trial
— SPLENEVAC-2Official title:
Evaluation of Immunological Response Following a Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients
| Verified date | October 2022 |
| Source | Assistance Publique - Hôpitaux de Paris |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This research is a multi-center French randomized and double blind phase IIb clinical trial evaluating 2 revaccination strategies against pneumococcal infections among splenectomised patients. The main objective is to evaluate at M13 the immunological response of 2 pneumococcal revaccination strategies (combined revaccination by a boost dose of PCV13 following 12 months later by PPS23, versus PPS23 alone) in splenectomised adults.
| Status | Active, not recruiting |
| Enrollment | 39 |
| Est. completion date | June 2024 |
| Est. primary completion date | June 2023 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: 1. Age = 18 years 2. Splenectomised patients. 3. For patients not enrolled in SPLENEVAC clinical trial: presence of Jolly Body at blood smear and spelenectomy confirmation by abdominal ultrasound. 4. Vaccinated according to the schedule of SPLENEVAC clinical trial (PCV13 / PPS23 two months later (until +4 months)), enrolled or not from this study. Vaccination of PPS23 must have been administered 5 years - 6 months/+ 1 year before inclusion. 5. Patients will be followed during the 24 months from the inclusion visit. 6. Patients must give written informed consent prior to any trial procedure. 7. Women of childbearing age must have an effective contraception during the first 13 months of the study. 8. Patients must be covered by social security regimen or equivalent. Exclusion Criteria: 1. History of pneumococcal revaccination in the last five years. 2. Having received any another vaccines within 4 weeks prior to enrolment or who is planning to receive any vaccine (for example: ZOSTAVAX®) within the first 13 months of the study (excepted seasonal influenza vaccine which is permitted 4 weeks before and after each vaccination visit of the study and then allowed at any time during the study follow up. Furthermore, the vaccination against Sars-CoV-2 is allowed during the study with a minimum interval of 14 days between pneumococcal vaccine and Sars-Cov-2 vaccine injection) 3. History of known allergies to any component of both study vaccines (active substances, excipients or diphtheria toxoid). 4. History of anaphylactic reaction following vaccination. 5. Infusion of immunoglobulins within the three months preceding the inclusion. 6. Any pathology or condition that may impair the immune response, apart from splenectomy: immunosuppressive therapy in progress or in the 6 months prior to inclusion, hematopoietic stem cells allo / autograft, primary immunodeficiency, nephrotic syndrome, progressive neoplasia, evolutive cancer, cirrhosis, known infection to HIV and / or hepatitis B virus (HBV) (HBs Ag +) and / or hepatitis C virus (HCV), taking corticosteroids > 10mg for more than 14 days within the month preceding the inclusion , inhaled corticosteroid and cutaneous topical being allowed. 7. Coagulation disorder contra-indicating intramuscularly injections. 8. Acute respiratory tract infection or severe acute febrile illness or systemic reaction which could represent a significant risk in case of vaccination within the month before inclusion. 9. Pregnancy, breastfeeding or positive pregnancy test up to 13 months after inclusion. 10. History of suspected or documented invasive pneumococcal infection within the year before inclusion. 11. Immunosuppressive factors associated. 12. Enrolment in any other clinical trial during the whole trial period except observational study. 13. Adults under protection |
| Country | Name | City | State |
|---|---|---|---|
| France | CIC 1417 Cochin-Pasteur - GH Broca-Cochin-Hôtel-Dieu | Paris |
| Lead Sponsor | Collaborator |
|---|---|
| Assistance Publique - Hôpitaux de Paris | CIC 1417 Cochin-Pasteur, EUCLID Clinical Trial Platform, I-REIVAC Innovative Clinical Research Network In Vaccinology, Recherche Clinique Paris Descartes Necker Cochin Sainte Anne |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Immunogenicity | Immune response at M13 against minimum of 5 of the 9 serotypes analysed (9 serotypes among the 12 common serotypes to both PPS23 and PCV13: 1, 3, 6B, 7F, 9V, 14, 19A, 19F, and 23F) in each arm.
A responder to a serotype is defined as a four-fold increase of the rate of OpsonoPhagocytic Assay (OPA) compared to baseline (M0) and titer = Lower Limit of Quantification (LLOQ). |
at Month 13 | |
| Secondary | Enzyme-linked immunosorbent assay (ELISA) antibody dosages | ELISA antibody concentration against 9 common serotypes (1, 3, 6B, 7F, 9V, 14, 19A, 19F and 23F), and, the proportion of positive serotypes: serotype is considered positive if the immunoglobulin G (IgG) antibody concentration in ELISA shows a two-fold increase from baseline (M0) in each arm from baseline. | Month 0 to Month 24 | |
| Secondary | Enzyme-linked immunosorbent assay (ELISA) antibody dosages | ELISA antibody concentration against 9 common serotypes (1, 3, 6B, 7F, 9V, 14, 19A, 19F and 23F), and, the proportion of positive serotypes: serotype is considered positive if the IgG antibody concentration is = 1µg/ml in each arm from baseline. | Month 0 to Month 24 | |
| Secondary | Enzyme-linked immunosorbent assay (ELISA) antibody dosages | ELISA antibody concentration against 9 common serotypes (1, 3, 6B, 7F, 9V, 14, 19A, 19F and 23F), and, the proportion of positive serotypes: serotype is considered positive if the IgG antibody concentration shows a two-fold increase from baseline (M0) in each arm and IgG = 1µg/ml from baseline. | Month 0 to Month 24 | |
| Secondary | Titration of OPA - | OPA titers against 9 common serotypes (1, 3, 6B, 7F, 9V, 14, 19A, 19F and 23F) and the proportion of positive serotype: serotype is considered positive if the antibody titer shows a four-fold increase from baseline (M0). | at Month 0, Month 13 and Month 24 | |
| Secondary | Titration of OPA - | OPA titers against 9 common serotypes (1, 3, 6B, 7F, 9V, 14, 19A, 19F and 23F) and the proportion of positive serotype: serotype is considered positive if the antibody titer = LLOQ. | at Month 0, Month 13 and Month 24 | |
| Secondary | Titration of OPA - | OPA titers against 9 common serotypes (1, 3, 6B, 7F, 9V, 14, 19A, 19F and 23F) and the proportion of positive serotype: serotype is considered positive if the antibody titer shows a four-fold increase from baseline (M0) and titer = LLOQ. | at Month 0, Month 13 and Month 24 | |
| Secondary | ELISA antibody dosages | ELISA antibody concentration against 3 uncommon specific serotypes of PPS23 (12F, 10A and15B) and the proportion of positive serotypes: serotype is considered positive if the IgG antibody concentration shows a two-fold increase from baseline (M12) in each arm and IgG = 1 µg/ml | at Month 12, Month 13 and Month 24 | |
| Secondary | ELISA antibody dosages | ELISA antibody concentration against 3 uncommon specific serotypes of PPS23 (12F, 10A and 15B) and the proportion of positive serotypes: serotype is considered positive if the IgG antibody concentration shows a two-fold increase from baseline (M12) in each arm. | at Month 12, Month 13 and Month 24 | |
| Secondary | ELISA antibody dosages | ELISA antibody concentration against 3 uncommon specific serotypes of PPS23 (12F, 10A and 15B) and the proportion of positive serotypes: serotype is considered positive if the IgG antibody concentration in ELISA is = 1µg/ml in each arm. | at Month 12, Month 13 and Month 24 | |
| Secondary | Sustainability and evolution of the immune response | Measure of ELISA concentration and OPA titers for the 9 PCV13 serotypes in each arm. | at Month 0 and Month 24 | |
| Secondary | ELISA antibody dosages | ELISA antibody concentration against 9 common specific serotypes (1, 3, 6B, 7F, 9V, 14, 19A, 19F and 23F) and the proportion of positive serotype: serotype is considered positive if the IgG antibody concentration in ELISA and shows a two-fold increase from baseline (M0) in each arm in SPLENEVAC 1 | at Month 3 | |
| Secondary | Percentage of patients presenting local or systemic reactions post-immunization | Number of subjects with local and systemic reactions following vaccinations (tolerability) in each arm. | Month0 to Month 24 |